Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of dupilumab in pediatric atopic dermatitis
2023-509425-53-00Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 3, open-label trial of dupilumab in atopic dermatitis (AD) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Rate of treatment-emergent adverse events per participant year, Participants with at least one treatment-emergent adverse event per participant year and 4 more. Started Nov 2015; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2023-509425-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509425-53-00.